<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332656</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10260</org_study_id>
    <secondary_id>2010-024631-16</secondary_id>
    <secondary_id>U1111-1118-5437</secondary_id>
    <nct_id>NCT01332656</nct_id>
  </id_info>
  <brief_title>Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel</brief_title>
  <acronym>OPSALIN</acronym>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus&#xD;
      placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with&#xD;
      paclitaxel and carboplatin.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To compare the overall survival (OS) between the 2 treatment arms&#xD;
&#xD;
        -  To compare the objective response rate (RR) between the 2 treatment arms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will continue until disease progression or unacceptable toxicity or consent&#xD;
      withdrawal. A minimum of 6 cycles of the combined therapies should be administered, unless&#xD;
      progression occurs before or safety reasons cause the discontinuation of one or two drugs of&#xD;
      the combination therapies. In case of no progression, it will be investigator's decision to&#xD;
      continue or not the study treatment after 6 cycles according to his clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (RR)</measure>
    <time_frame>approximately 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombrabulin, Paclitaxel and Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Paclitaxel and Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombrabulin (AVE8062)</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. Histological and/or cytological diagnosis of epithelial ovarian carcinoma, fallopian&#xD;
             tube cancer, or primary peritoneal carcinoma.&#xD;
&#xD;
          4. Completion of maximum one previous line of chemotherapy containing a platinum agent.&#xD;
             Neoadjuvant/adjuvant treatment that include a surgical procedure will be considered as&#xD;
             one line if platinum-based.&#xD;
&#xD;
          5. Documented sensitivity to a platinum based chemotherapy regimen.&#xD;
             &quot;Platinum-sensitivity&quot; is defined by a relapse more than 6 months after last dose of&#xD;
             platinum-based chemotherapy.&#xD;
&#xD;
          6. Measurable progressive disease: Measurable disease (as defined by RECIST 1.1) is&#xD;
             defined as at least one lesion that can be accurately measured in at least one&#xD;
             dimension (longest diameter to be recorded). Each lesion must be at least 10mm when&#xD;
             measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes&#xD;
             must be &gt;15 mm in short axis when measured by CT or MRI. In case of a single&#xD;
             measurable lesion, this should not be previously irradiated.&#xD;
&#xD;
          7. ECOG performance status ≤2&#xD;
&#xD;
          8. Life expectancy more than 12 weeks&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. History of uncontrolled brain metastases, spinal cord compression, or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
          2. History of another neoplasm. Adequately treated basal cell or squamous skin cancer, or&#xD;
             in situ cervical cancer, or any other cancer from which the patient has been&#xD;
             disease-free for &gt;5 years are allowed.&#xD;
&#xD;
          3. Participation in another clinical trial and any concurrent treatment with any&#xD;
             investigational drug or anti-tumor therapy or radiotherapy within 21 days prior to&#xD;
             randomization (or 28 days for those therapies with a schedule of administration every&#xD;
             4 weeks and except for nitrosoureas, mitomycin which may not be used up to 6 weeks&#xD;
             prior to the first cycle provided that patients do not have residual signs of any&#xD;
             toxicity). No wash-out is required for hormonotherapy which has to be discontinued&#xD;
             before the first cycle.&#xD;
&#xD;
          4. Any severe acute or chronic medical condition, which could impair the ability of the&#xD;
             patient to participate in the study or interfere with interpretation of study results.&#xD;
&#xD;
          5. Pregnancy or breast-feeding. Positive serum or urine pregnancy test prior to&#xD;
             randomization.&#xD;
&#xD;
          6. Patient with reproductive potential who do not agree to use accepted and effective&#xD;
             method of contraception during the study treatment period and for at least 6 months&#xD;
             after the completion of the study treatment. The definition of &quot;effective method of&#xD;
             contraception&quot; will be based on the investigator's judgment. Effective method of&#xD;
             contraception should also be adapted to local regulations.&#xD;
&#xD;
          7. Inadequate organ function including: neutrophils &lt;1.5 x 10^9/L; platelets &lt;100 x&#xD;
             10^9/L; creatinine ≥ 1.5 ULN. If creatinine ≥ ULN, the calculated creatinine clearance&#xD;
             should be ≥ 60 ml/min (as per Cockcroft Formula). Total bilirubin not within normal&#xD;
             limit and ALT/AST/AP &gt;2.5 times the upper normal limits of the institutional norms. An&#xD;
             increase of AP up to grade 2 would be accepted only if this increase is related to the&#xD;
             presence of bone metastases. Bone specific isoenzyme AP should be evaluated.&#xD;
&#xD;
          8. Urine protein-creatinin ratio (UPCR) &gt;1 (urinanalysis on morning spot urine) or&#xD;
             proteinuria &gt;500 mg/24h&#xD;
&#xD;
          9. Pre-existing peripheral neuropathy &gt; grade 1 according to the NCI CTCAE V.4.03&#xD;
&#xD;
         10. Pre-existing hearing impairment &gt; grade 1&#xD;
&#xD;
         11. Known hypersensitivity due to taxanes and /or polysorbate 80 or any other&#xD;
             compound/excipients of the study drug combination&#xD;
&#xD;
         12. Discontinuation of previous treatment with paclitaxel and/or carboplatin for toxicity&#xD;
             reason&#xD;
&#xD;
         13. Other serious illness or medical conditions such as (but not restricted):&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  Superior vena cava syndrome&#xD;
&#xD;
               -  Pericardial effusion requiring intervention (drainage)&#xD;
&#xD;
         14. Documented medical history of myocardial infarction, documented angina pectoris,&#xD;
             arrhythmia especially severe conduction disorder such as second or third-degree&#xD;
             atrioventricular block, stroke, or history of arterial or venous thrombo-embolism&#xD;
             within the past 6 months still requiring anticoagulants.&#xD;
&#xD;
         15. Cardiac Troponin at levels that exceed the normal ranges values defined by the&#xD;
             laboratory&#xD;
&#xD;
         16. Uncontrolled hypertension within 3 months prior to study treatment or patient with&#xD;
             organ damage related to hypertension.&#xD;
&#xD;
         17. Patient with LVEF value lower than institution inferior normal limit, evaluated by&#xD;
             echocardiography or angiocardiography&#xD;
&#xD;
         18. 12-lead ECG:&#xD;
&#xD;
               -  Infarction Q-wave,&#xD;
&#xD;
               -  ST segment depression or elevation ≥1 mm in at least 2 contiguous leads&#xD;
&#xD;
               -  QT/QTc-Time &gt; 450ms&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840202</name>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <zip>33919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056005</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Novy Jicin</city>
        <zip>74101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203004</name>
      <address>
        <city>Zlin</city>
        <zip>76275</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250006</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Paris Cedex 4</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616002</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616004</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616003</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616005</name>
      <address>
        <city>Warszawa</city>
        <zip>02-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616001</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643003</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804003</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804005</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804004</name>
      <address>
        <city>Kharkov</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804002</name>
      <address>
        <city>Lviv</city>
        <zip>70031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <disposition_first_submitted>November 18, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 18, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 21, 2015</disposition_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

